PharmAla Launches Prescriber’s Portal for Medical Professionals Focused on MDMA Therapy
03 mai 2024 11h00 HE
|
PharmAla Biotech
PharmAla launches new educational resource for prescribers of MDMA through the Special Access Program
Global Psychiatry Collaboration and Licensing Deals Directory, 2019-2024: Deal Trends, Leading Deals by Value, Most Active Dealmakers, Financials Terms, and More
26 avr. 2024 10h16 HE
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Psychiatry Collaboration and Licensing Deals 2019-2024" report has been added to ResearchAndMarkets.com's offering.Psychiatry Collaboration and...
PharmAla Closes Private Placement and Concurrent Debt Settlement
19 avr. 2024 08h35 HE
|
PharmAla Biotech
PharmAla completes private placement and concurrent debt settlement with Advisor.
Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
15 avr. 2024 07h00 HE
|
Axsome Therapeutics, Inc.
AXS-05 in Alzheimer’s disease agitation data featured in oral plenary session New data for AXS-07 in migraine demonstrating efficacy in pooled analysis Presentations on cognitive and wake promoting...
PsyCan Welcomes Expansion of Insurance Coverage for Psychedelic-Assisted Therapy in Alberta
02 avr. 2024 09h30 HE
|
Psychedelics Canada
Psycan announces that Blue Cross Alberta has issued a notice to prescribers that it will reimburse patients for Psychedelic-Assisted Therapy
Beacon Behavioral Partners Celebrates Expansion Across the Southeast United States
15 févr. 2024 15h11 HE
|
Beacon Behavioral Partners
Beacon Behavioral Partners, a leading provider of support services for behavioral health practices, announces the success of its expanding network.
Developing Biological Markers to Improve Clinical Care in Autism - A Free Webinar from the Brain & Behavior Research Foundation
06 févr. 2024 10h15 HE
|
Brain & Behavior Research Foundation
New York, Feb. 06, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Developing Biological Markers to Improve Clinical Care in Autism” on...
FDA Clears Magstim Transcranial Magnetic Stimulation System Horizon 3.0 with StimGuide Pro
30 janv. 2024 09h18 HE
|
Magstim EGI
FDA clears Magstim TMS System Horizon 3.0 with StimGuide Pro providing treatment for patients patients with depressive or obsessive-compulsive conditions
Psychiatry Clinic Market Forecast to Reach USD 123.67 Billion by 2030 with Comprehensive Vendor Analysis
21 janv. 2024 20h28 HE
|
Research and Markets
Dublin, Jan. 21, 2024 (GLOBE NEWSWIRE) -- The "Global Psychiatry Clinic Market by Age Group (Adult, Pediatric), Therapy Type (Behavioral therapy, Cognitive therapy, Interpersonal therapy) - Forecast...
Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression Patients
04 janv. 2024 02h00 HE
|
Nexstim Oyj
Press release, Helsinki, 4 January 2024 at 9 AM (EET) Nexstim Agrees on a Strategic Investment into a Management Services Organization of a New Jersey Based Clinic Providing Treatments for Depression...